The state of Texas currently has 17 active clinical trials seeking participants for NASH - Nonalcoholic Steatohepatitis research studies. These trials are conducted in various cities, including Houston, Dallas, San Antonio and Austin.
Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects
Recruiting
This study is a phase 2 study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects with Biopsy Confirmed NASH
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
10/23/2023
Locations: Texas Digestive Disease Consultants, P.A. (TDDC), Arlington, Texas +8 locations
Conditions: NASH - Nonalcoholic Steatohepatitis
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Recruiting
This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/28/2023
Locations: Site 211, Austin, Texas +3 locations
Conditions: Nonalcoholic Steatohepatitis (NASH)
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
Recruiting
To evaluate, in patients with suspected NASH referred for liver biopsy, the diagnostic performance of CT1 at discriminating those with NAS≥4 & F≥2 from those without.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
09/07/2023
Locations: Liver Center of Texas, Dallas, Texas
Conditions: NASH - Nonalcoholic Steatohepatitis
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Texas Clinical Research Institute, Arlington, Texas +11 locations
Conditions: Non Alcoholic Steatohepatitis (NASH)
LITMUS Imaging Study
Recruiting
The LITMUS Imaging Study is a prospectively recruited, observational study of patients with histologically characterised non-alcoholic fatty liver disease (NAFLD). It aims to evaluate the diagnostic performance of imaging biomarkers (ultrasound elastography and magnetic resonance biomarkers) against NAFLD histological scores in a cross-sectional analysis and the natural history of NAFLD in a longitudinal study.
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
07/26/2022
Locations: Pinnacle Clinical Research, San Antonio, Texas
Conditions: NAFLD, NASH, NASH - Nonalcoholic Steatohepatitis, Fibrosis, Liver, Steatosis of Liver